Jax Spine & Pain Centers in Jacksonville, Fla., has enrolled the first patient in the Upgrade Study, which will examine long-term, real-world outcomes to understand the effect of Medtronic's Differential Target Multiplexed programming for spinal cord stimulation patients.
Administered via Medtronic's Intellis platform, DTM SCS therapy is a programming option used to treat patients with chronic pain. DTM was developed by Stimgenics, which was acquired by Medtronic last year.
"DTM therapy is the first tailored SCS approach intentionally developed from a novel scientific concept and demonstrated in a [randomized controlled trial]," Charlie Covert, vice president and general manager of Medtronic's pain business, said in a Feb. 23 news release. "We're excited to see another study expand on the strong body of evidence that exists today."
The study, sponsored by Celéri Health, will enroll up to 1,700 patients at 20 to 30 centers in the U.S.
Interventional spine specialist Michael Haines, MD, enrolled the first patient on Jan. 29.